Free Trial

Creo Medical Group PLC (LON:CREO) Insider Acquires £200,430 in Stock

Creo Medical Group logo with Medical background

Creo Medical Group PLC (LON:CREO - Get Free Report) insider Kevin Crofton bought 1,179,000 shares of the stock in a transaction on Friday, December 13th. The stock was purchased at an average cost of GBX 17 ($0.22) per share, for a total transaction of £200,430 ($254,288.25).

Kevin Crofton also recently made the following trade(s):

  • On Monday, October 21st, Kevin Crofton bought 2,916,666 shares of Creo Medical Group stock. The shares were acquired at an average price of GBX 24 ($0.30) per share, with a total value of £699,999.84 ($888,099.26).

Creo Medical Group Price Performance

Shares of CREO stock traded up GBX 0.62 ($0.01) during trading hours on Monday, hitting GBX 17.50 ($0.22). The company's stock had a trading volume of 795,444 shares, compared to its average volume of 720,937. The company has a current ratio of 3.24, a quick ratio of 2.19 and a debt-to-equity ratio of 29.96. Creo Medical Group PLC has a twelve month low of GBX 12 ($0.15) and a twelve month high of GBX 50 ($0.63). The stock has a market cap of £63.31 million, a price-to-earnings ratio of -291.67 and a beta of 0.86. The business has a fifty day moving average of GBX 18.21 and a 200-day moving average of GBX 26.35.

Creo Medical Group Company Profile

(Get Free Report)

Creo Medical Group PLC, through its subsidiaries, researches, develops, manufactures, and sells medical devices and instruments in the United Kingdom. It is developing CROMA, an energy platform that combines bipolar radiofrequency for precise localized cutting and microwave energy for controlled coagulation, to provide physicians with flexible, accurate, and highly controllable devices delivered through a flexible endoscope.

See Also

Should you invest $1,000 in Creo Medical Group right now?

Before you consider Creo Medical Group, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Creo Medical Group wasn't on the list.

While Creo Medical Group currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Broadcom Hits $1 Trillion – Can This AI Powerhouse Go Higher?

Broadcom Hits $1 Trillion – Can This AI Powerhouse Go Higher?

AVGO is up 30% since earnings: could Broadcom be the next member of the Magnificent Seven? Can it sustain this momentum or is a pullback on the horizon?

Related Videos

Broadcom’s Momentum Returns: Will It Reach New Highs?
Why Congress Is Betting Big on Broadcom in 2024
Top 3 Stocks Members of Congress are Buying Ahead of the Election

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines